First European site opened in France and Patient Recruitment Commences in Lupuzor’s™ Pivotal Phase III Study

10th March 2016 - 2:11 pm

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its pivotal Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease.

ImmuPharma is pleased to confirm that the first European site in Bordeaux, France is open and the patient recruitment process in Europe has now commenced. This follows on from the Company’s recent announcement in February that the first US Lupus patients had commenced dosing.
Recruitment in this pivotal Phase III study for Lupuzor™ will occur in up to 45 investigator sites. 10 sites in United States and 35 sites in Europe to include France, Hungary, Poland, Germany, Czech Republic, Italy and the UK.
Further updates on the progression of the Lupuzor™ Phase III trial will be announced, as appropriate, as the trial progresses. Progress on the trial can also be seen at: www.ClinicalTrials.gov/lupuzor
Commenting on this event, Tim McCarthy, Chairman, said: “Following the initial US sites being opened and the first Lupus patients having commenced dosing we are delighted that we have hit another key milestone with patient recruitment started in our first European site in France. We look forward to providing further positive updates on this Lupuzor™ Phase III study as it progresses throughout this year and 2017.” 
Share this article

Leave a comment